New drugs for HIV therapy
- 1 January 2002
- journal article
- review article
- Published by Wolters Kluwer Health in AIDS
- Vol. 16, S135-S144
- https://doi.org/10.1097/00002030-200216004-00019
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- HIV fusion and its inhibition.Antiviral Research, 2001
- Recombinant CD4‐IgG2 in Human Immunodeficiency Virus Type 1–Infected Children: Phase 1/2 StudyThe Journal of Infectious Diseases, 2000
- In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632Antimicrobial Agents and Chemotherapy, 2000
- Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samplesAIDS, 2000
- BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral AgentsAntimicrobial Agents and Chemotherapy, 2000
- Current Evidence and Future Directions for Targeting HIV EntryJAMA, 2000
- Viral phenotype and CCR5 genotypeNature Medicine, 1999
- AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptorNature Medicine, 1998
- Expression and Characterization of CD4-IgG2, a Novel Heterotetramer That Neutralizes Primary HIV Type 1 IsolatesAIDS Research and Human Retroviruses, 1995
- Recombinant Soluble CD4 Therapy in Patients with the Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related ComplexAnnals of Internal Medicine, 1990